Omnibus spending bill
This article was originally published in The Tan Sheet
Executive Summary
House, Senate agree to conference report on FY 2003 approps bill Feb. 13, providing $413.3 mil. for CFSAN, $426.7 mil. for CDER. Total FDA budget is $1.63 bil., including $222.9 mil. in PDUFA fees. Funding levels are similar to those in version passed by lower chamber (1"The Tan Sheet," Jan. 27, 2003, In Brief)...
You may also be interested in...
Omnibus appropriations signed
President Bush signs H.J. Res. 2 Feb. 20, providing federal government $397.4 bil. for FY 2003. House and Senate agreed to conference report Feb. 13 (1"The Tan Sheet" Feb. 17, 2003, In Brief)...
Omnibus bill clears Senate
Amendment that would allocate $10 mil. in FDA funding "for the continuance of methamphetamine reduction efforts" passes Senate by voice vote Jan. 23. Proposed by Sen. Charles Grassley (R-Iowa), amendment is one of more than 200 considered by upper chamber before it passed omnibus spending package (H J Res 2) the same day in a 69-29 vote. Measure would provide FDA with $1.63 bil. in FY 2003, of which $412.4 mil. would be allocated to CFSAN, $426.2 mil. to CDER. NCCAM would receive $114.1 mil., roughly $9 mil. above House-approved level. Next step is conference with lower chamber, which passed its omnibus package Jan. 8; Hill sources say conference process could be resolved by the Presidents' Day recess, although Congress faces "tremendous hurdles"...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.